| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | 0.079 | 0.01 |
| mRNA | VX-11e | GDSC1000 | pan-cancer | AAC | 0.083 | 0.01 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | 0.091 | 0.01 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | 0.082 | 0.01 |
| mRNA | BRD-K92856060 | CTRPv2 | pan-cancer | AAC | 0.089 | 0.01 |
| mRNA | SKI-II | CTRPv2 | pan-cancer | AAC | 0.09 | 0.01 |
| mRNA | Compound 1541A | CTRPv2 | pan-cancer | AAC | 0.095 | 0.02 |
| mRNA | KIN001-260 | GDSC1000 | pan-cancer | AAC | 0.078 | 0.02 |
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | 0.076 | 0.02 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | 0.11 | 0.02 |